| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

9 March 2021

ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference

22 February 2021

ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020

11 February 2021

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

15-17 March 2021

33rd Annual ROTH Conference

10-11 March 2021

14th Annual European Life Sciences CEO Forum 2021

11 March 2021

BioCapital Europe 2021

9-10 March 2021

H.C. Wainwright Global Life Sciences Conference

9-14 March 2021

15th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD 2021

16-18 February 2021

2021 BIO CEO & Investor Digital Conference

10 February 2021

ORYZON to present new clinical data and corporate updates at conferences in February and March

Pagination

First page «
Previous page ‹
Page 24
Page 25
Page 26
Page 27
Current page 28
Page 29
Page 30
Page 31
Page 32
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel